CN1763213A - Synthesis method of 5-fluorocytidine - Google Patents
Synthesis method of 5-fluorocytidine Download PDFInfo
- Publication number
- CN1763213A CN1763213A CN 200510029428 CN200510029428A CN1763213A CN 1763213 A CN1763213 A CN 1763213A CN 200510029428 CN200510029428 CN 200510029428 CN 200510029428 A CN200510029428 A CN 200510029428A CN 1763213 A CN1763213 A CN 1763213A
- Authority
- CN
- China
- Prior art keywords
- reaction
- flurocytosine
- damping fluid
- nucleosides
- transferring enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Saccharide Compounds (AREA)
Abstract
The present invention provides one kind of 5-fluorocytidine synthesizing process, which synthesizes 5-fluorocytidine with thymine and 5-fluorocytosine under the catalysis of deoxyribotransferase. The said process has no radical protection and deprotection operation, less synthesis steps, raised destination product yield and lowered synthesis cost and no organic solvent caused environment pollution.
Description
Technical field
The present invention relates to a kind of synthetic method of 5-flurocytosine nucleosides, relate to a kind of enzymatic synthesis method of 5-flurocytosine nucleosides specifically.
Background technology
β-D-2 ', 3 '-two deoxidations are two, and dehydrogenation-5-flurocytosine nucleosides (D-D4FC) is the s-generation does not have toxic side effect to the human body plastosome nucleoside analog (Schinazi, R.; Ma, L.; Shi, J.; Liotta, D.; Faraj, A.; Sommadossi, J.P.Abstract 557/41174,12th worldAIDS conf, Geneva, June 28-July 3,1998.), be a kind of HIV efficiently and HBV selective depressant, can suppress duplicating of HIV and HBV in vitro and in vivo.It is reported that it can be restrained AZT, ddC, ddI, D4T and 3TC have drug-fast HIV-1 C-type virus C, simultaneously, HBV are also had very strong supression effect (Hammond, J.; Schinazi, R.; Schlueter-Wirtz, S.; Mellors, J.Abstract 597,6th Conference on Retroviruses andOpportunistic Infections, Chicago, January 31-fuebuary 4,1999.).Owing in cell system and body, show good pharmacy dynamics and hypotoxicity, be regarded as the potential good medicine of anti-HIV and HBV.This medicine is at the U.S., Germany and France's beginning phase ii clinical trial.
Up to the present, D-D4FC only has report (J Org Chem, 1992,57 (14): 3887 of chemical synthesis; J Med Chem, 1999,42 (5): 859; Bioorg Med Chem Lett, 1998,8 (22): 3245; J Med Chem, 1999,42 (5): 859; Carbohydrate Res.1997,300 (4): 375), the yield of these synthetic routes is all lower, and the mole total recovery is all about 10%; The condition of chemosynthesis is relatively harsher, needs operation at low temperatures, and the industrialization difficulty is bigger; In the process of chemosynthesis, need to use expendable heavy metal catalyst, not only toxic to workman's health, and also also very unfriendly to environment, do not meet the green friendly chemical theme of advocating now.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of synthetic method of 5-flurocytosine nucleosides, to solve synthetic cost height in the prior art, synthetic route is long, yield is low, photolytic activity is low shortcoming.
The invention discloses a kind of synthetic method of 5-flurocytosine nucleosides, this method comprises the steps:
The thymidine of structural formula in the reaction formula 1 is carried out the base permutoid reaction with 5-flurocytosine in the damping fluid that contains the ribodesose transferring enzyme, 30-45 ℃ was reacted 20-30 hour; The dried residue of reaction solution is the 5-flurocytosine nucleosides with methyl alcohol or dichloromethane extraction, the fluorine-containing nucleoside analog that obtains structural formula 2;
Wherein reaction formula is:
Wherein damping fluid is KH
2PO
4A kind of in damping fluid, citrate buffer solution or the water.
Add the ribodesose transferring enzyme in the reaction process.
Preferred synthetic method is:
The thymidine of 100-150mg 50mmol is carried out the base permutoid reaction with the 5-flurocytosine of 100-150mg 50mmol in the damping fluid that contains 4ml ribodesose transferring enzyme, 30-45 ℃ of constant temperature was with 100-200r/min tachyphylaxis 20-30 hour; The dried residue of reaction solution methyl alcohol or the dichloromethane extraction of 10-30ml, the fluorine-containing nucleoside analog that obtains structural formula 2 is the 5-flurocytosine nucleosides.
Adopt the synthetic D-D4FC of biological enzyme, have following advantage
(1) enzyme catalysis efficient height, the catalytic efficiency of enzyme exceeds 10 than general chemical catalysis
6～10
13Doubly.In enzymic catalytic reaction, avoided radical protection and de-protected operation in chemosynthesis, shortened the synthetic step, improved the yield of target product, simultaneously, reduced synthetic cost.Experimental result shows, has been brought up to about 25% by about 10% of chemical synthesis with the productive rate of the synthetic D-D4FC of enzyme process catalysis, and experimental procedure has shortened to a step by seven steps of chemical synthesis.
(2) good reaction selectivity, most of enzymes have the specificity of height, and a certain gene of catalysis that can be single-minded rapidly or the reaction of a certain specific position synthesize the asymmetric compound with high optical activity.Experimental result shows that the ee value of synthesizing D-D4FC with enzyme process catalysis has reached 99%
(3) carry out in the aqueous solution of temperature of reaction under normal temperature (37-45 ℃) normal pressure of the synthetic D-D4FC of enzyme catalysis, mild condition, control is easy, and side reaction is few, the environmental pollution of having avoided the organic solvent in the chemical synthesis to bring simultaneously.
Embodiment:
Embodiment 1
Get unsaturated thymidine (D-D4T) 1112mg (50mmol), 5-flurocytosine (5-FC) 124mg (100mmol), KH
2PO
4Damping fluid 30mL (pH 6.35), the homemade ribodesose transferring enzyme of 4ml liquid send out with 150r/min vibration in water bath with thermostatic control and answer 20-24h in the Erlenmeyer flask of 100ml.Being reflected at boils in the boiling water boils 5min with stopped reaction.Reaction solution is frozen drying, and residue extracts with the 10ml ethanol/methylene, and extraction liquid launches with TLC, obtains product 214.96mg, Y:16.8%.
Embodiment 2
Get unsaturated thymidine (D-D4T) 1 112mg (50mmol), 5-flurocytosine (5-FC) 124mg (100mmol), KH
2PO
4Damping fluid 30mL (pH 6.35), the homemade ribodesose transferring enzyme of 4ml liquid send out with 150r/min vibration in water bath with thermostatic control and answer 20-24h in the Erlenmeyer flask of 100ml.Being reflected at boils in the boiling water boils 5min with stopped reaction.Reaction solution is frozen drying, residue 30ml methanol extraction, and concentrating under reduced pressure gets solid mixture.Solid mixture is crossed silica gel column chromatography (20% CH
3OH/CH
2Cl
2, v/v) purifying gets product 227.5mg, Y:24.6%.
Embodiment 3
Get unsaturated thymidine (D-D4T) 1112mg (50mmol), 5-flurocytosine (5-FC) 124mg (100mmol), citrate buffer solution 30mL (pH 6.35), the homemade ribodesose transferring enzyme of 4ml liquid is sent out with 150r/min vibration in water bath with thermostatic control and is answered 20-24h in the Erlenmeyer flask of 100ml.Being reflected at boils in the boiling water boils 5min with stopped reaction.Reaction solution is frozen drying, residue 30ml methanol extraction, and concentrating under reduced pressure gets solid mixture.Solid mixture is crossed silica gel column chromatography (20% CH
3OH/CH
2Cl
2, v/v) purifying gets product 227.0mg, Y:24.1%.
The TLC method is adopted in qualitative analysis in the reaction process.With activated silica gel G plate is carrier, methylene dichloride-methyl alcohol-water (8: 2: 0.25v/v) be developping agent, the ultraviolet colour developing.The R of D-D4T, D-D4FC, 5-FC and thymus pyrimidine
fReference value is respectively the analysis of 0.82,0.61,0.29 and 0.05 substrate and product and adopts the HPLC method.Adopt chromatographic column Diamonsil C
18, Φ 4.6 * 150mm; With the 15-35% methanol is that moving phase is carried out tonsure washing, flow velocity 0.9mL/min; Detect at the 270nm place.The t of D-D4FC, 5-FC, D-D4T and thymus pyrimidine
RReference value is respectively 7.06min, 5.20min, 3.86min and 2.71min.HPLC analyzes specimen in use and all takes from organic phase, and calculates productive rate according to substrate starting point concentration in the organic phase and production concentration.
The spectrum analysis data are as follows:
1H?NMR(DMSO-d
6)：δ8.04(d，J＝7.6Hz，1H，H-6)，7.77(bs，1H，NH)，7.64(bs，1H，NH)，6.82(bs，1H，H-1′)，6.39(d，J＝7.6Hz，1H，H-3′)，5.83(d，J＝6.0Hz，1h，H-2′)，5.11(t，J＝6.0Hz，1H，OH)，4.77(bs，1H，H-4′)，3.41-3.59(m，2H，H-5′)
19F?NMR(DMSO-d
6)：δ171.36(J＝8.0Hz)
EI?mass?calcd?for?C
9H
11FN
3O
3(M+H
+)：228.0784，found：228.0784UV(MeOH)：max?280nm。
Claims (3)
1. the synthetic method of a 5-flurocytosine nucleosides is characterized in that this method comprises the steps:
The thymidine of structural formula in the reaction formula 1 is carried out the base permutoid reaction with 5-flurocytosine in the damping fluid that contains the ribodesose transferring enzyme, 37-42 ℃ was reacted 20-30 hour; The dried residue of reaction solution is the 5-flurocytosine nucleosides with methyl alcohol or dichloromethane extraction, the fluorine-containing nucleoside analog that obtains structural formula 2;
Wherein reaction formula is:
Wherein damping fluid is KH
2PO
4A kind of in damping fluid, citrate buffer solution or the water.
2. the synthetic method of 5-flurocytosine nucleosides according to claim 1 is characterized in that adding in the reaction process ribodesose transferring enzyme.
3. the synthetic method of 5-flurocytosine nucleosides according to claim 1 and 2 is characterized in that this method comprises the steps:
The thymidine of 100-150mg 50mmol is carried out the base permutoid reaction with the 5-flurocytosine of 100-150mg 50mmol in the damping fluid that contains 4ml ribodesose transferring enzyme, 30-45 ℃ of constant temperature was with 100-200r/min tachyphylaxis 20-30 hour; The dried residue of reaction solution obtains the 5-flurocytosine nucleosides with methyl alcohol or the dichloromethane extraction of 10-30ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510029428XA CN100355901C (en) | 2005-09-06 | 2005-09-06 | Synthesis method of 5-fluorocytidine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510029428XA CN100355901C (en) | 2005-09-06 | 2005-09-06 | Synthesis method of 5-fluorocytidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1763213A true CN1763213A (en) | 2006-04-26 |
| CN100355901C CN100355901C (en) | 2007-12-19 |
Family
ID=36747532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510029428XA Expired - Fee Related CN100355901C (en) | 2005-09-06 | 2005-09-06 | Synthesis method of 5-fluorocytidine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100355901C (en) |
-
2005
- 2005-09-06 CN CNB200510029428XA patent/CN100355901C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100355901C (en) | 2007-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10519496B2 (en) | Labelled nucleotides | |
| US5428149A (en) | Method for palladium catalyzed carbon-carbon coulping and products | |
| US7427673B2 (en) | Labelled nucleotides | |
| US5783679A (en) | Purine nucleoside modifications by palladium catalyzed methods and oligonucleotides containing same | |
| JP2019500324A (en) | Nucleotide analogues | |
| KR102190852B1 (en) | Method of preparing oligomeric compounds using modified coupling protocols | |
| JP2003535102A (en) | Nucleotide analogs containing a reporter moiety and a polymerase enzyme block moiety | |
| Shi et al. | A stereospecific synthesis of L-deoxyribose, L-ribose and L-ribosides | |
| US8389703B1 (en) | Ribonucleoside analogs with novel hydrogen bonding patterns | |
| KR20190065341A (en) | Method of joining oligomeric compounds | |
| Zhang et al. | A divergent strategy for constructing a sugar library containing 2, 6-dideoxy sugars and uncommon sugars with 4-substitution | |
| CN102127135A (en) | Preparation method of pyrimidine nucleoside compound or purine nucleoside compound | |
| CN102690311A (en) | Preparation method for cytidine | |
| CN100355901C (en) | Synthesis method of 5-fluorocytidine | |
| CN109912672B (en) | Method for glycosylation of base by taking o-alkynyl phenol ether as leaving group | |
| WO2004101582A2 (en) | Thermolabile hydroxyl protecting groups and methods of use | |
| CN108409818B (en) | Method for synthesizing cytosine nucleoside | |
| JP4899014B2 (en) | Palladium-catalyzed nucleoside modification method using nucleophiles and carbon monoxide | |
| CN114456169B (en) | 3' -deoxy-3 ',4' -didehydroribonucleoside analogues and preparation method thereof | |
| JP2870901B2 (en) | Method for producing dideoxynucleoside derivative by selective hydrolysis | |
| EP0828750B1 (en) | Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide | |
| JPH0390096A (en) | Production of nucleoside derivative | |
| CN100350053C (en) | Enzymatic synthesis method of 6-chloropurine riboside | |
| Caballero et al. | Synthesis of (2′ S)‐2′‐Deoxy‐2′‐C‐methylpurine Nucleosides and Their Phosphoramidites | |
| JPH0717670B2 (en) | Method for producing nucleoside derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071219 Termination date: 20100906 |